Aarti Drugs Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/yv358nly3oqb3vgz7kq31xki.pdf

Key Takeaways


API Pricing & Demand Dynamics

Adhish Patil: "The thing is in the broad scenario, we just thought a month back that everything streamlined and everything will come back to normal. But again, things are quite volatile as of now to say anything. ... for us, frankly speaking, even if prices are lower, but if they are stable, then we can definitely make handsome margins."

Sayakha Ramp & Margin Bridge

Adhish Patil: "So 14% is quite doable. We are almost there. Now once the utilization of the two main greenfield projects what we have put up once that improves, then definitely 15% should be very easy. Once the Salicylic acid plant comes on track, then that drag will reduce on the overall P&L."

Salicylic Acid: The Deliberate Drag

Adhish Patil: "But then after we launched the capacity, Chinese players, they drastically dropped the pricing of salicylic acid, mainly to drive the competition out. That is the main purpose."

Metformin: Capacity, Approvals & Market Access

Adhish Patil: "The key challenge what we faced so far is that many of the European clients of Metformin are also operating in the US market, so they need a supplier who is both European as well as USFDA approved. And that is the main reason why we are going in for USFDA approval because that will open up not only the US market but also the huge European markets for us as well."

Regulated Markets & Formulations Build-Out


Specialty Chemicals & Competitive Position


Guidance & Commitments

CommitmentSpecificsTimeline
Captive consumption ramp80–90% captive intermediate consumption at Sayakha (vs 60–70% procured externally in Q1)December quarter
Gross margin improvementCaptive consumption to add roughly 1% in gross contributionAt peak utilization
Metformin USFDA capacityFresh ~500+ tons per month block constructed; file for USFDA inspection10–12 months to construct; supplies earliest after 12 months
Specialty Chemicals run rateQ1 performance (~₹82 crores) to repeatNext 3 quarters
Anti-dumping duty on salicylic acidGovernment decision expectedMost probably 1 more year
Volume growth10% to 15% volume growthOver next two years
EBITDA margin15% achievable once greenfield utilization improves and salicylic acid drag reducesNo specific date; conditional on utilization and pricing stability

Key Metrics

MetricQ1 FY27
Consolidated revenue₹703.6 cr, +19% YoY
Standalone revenue₹627.6 cr, +20% YoY; 89% of consolidated revenue
Standalone domestic revenue68% of standalone revenue, +25% YoY
Standalone export revenue32% of standalone revenue, +12% YoY
Consolidated EBITDA₹96.9 cr, +30% YoY
Consolidated EBITDA margin13.8%, +120 bps YoY; crossed ~14% after write-offs of aging Capital WIP
Consolidated PBT₹69.2 cr, +35% YoY
Consolidated PBT margin9.9%, +120 bps YoY
Consolidated PAT₹50.1 cr; Q1 FY26 PAT of ₹54.0 cr included a principal tax refund of ₹15 cr, excluding which growth impact would be +29% YoY
Formulations segment revenue₹81.6 cr, +8% YoY; exports contributed ~74%
API therapeutic mix: antibiotic35.0% of total API sales
API therapeutic mix: antidiabetic18.2% of total API sales
API therapeutic mix: antiprotozoal~18.5% of total API sales
API therapeutic mix: anti-inflammatory11.9% of total API sales
API therapeutic mix: antifungal10.2% of total API sales
Aggregate volume growth (company level)~3.5% YoY, domestic and export combined
Aggregate price growth (company level)~16–17% YoY
Sayakha facility utilization~65% in Q1 FY27, up from 30–40% in Dec and Mar quarters
Metformin capacity utilizationMid-80s% of ~1,400 tons per month
Metformin pricing movementUp ~15–20% compared to pre-war levels
Specialty Chemicals sales~₹82 cr in Q1, +149% growth
Methylamine production (Sayakha)~3,500 tons for the June quarter, ~60 tons per day
Salicylic acid production67 tons in the June quarter; capacity of 600 tons per month at ~70% utilization
Captive intermediate procurement from outside~60–70% in June quarter; expected to drop to 10–20% by Dec quarter